))
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases
Manage episode 457200374 series 3600068
Indhold leveret af ReachMD. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af ReachMD eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.
…
continue reading
Guest: Aaron Lisberg, MD
Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.
9 episoder
Del
